Literature DB >> 14988915

Extraglandular and intraglandular vascularization of canine prostate.

Miroslav Stefanov1.   

Abstract

The literature on the vascularization of the canine prostate is reviewed and the clinical significance of prostate morphology is described. Scanning Electron Microscopy (SEM), combined with improved corrosion casting methods, reveal new morphological details that promise better diagnostics and treatment but also require expansion of clinical nomenclature. A proposal is made for including two previously unnamed veins in Nomina Anatomica Veterinaria (NAV). The canine prostate has two lobes with independent vascularization. Each lobe is supplied through the left and right a. prostatica, respectively. The a. prostatica sprouts three small vessels (cranial, middle, and caudal) towards the prostate gland. A. prostatica is a small-size artery whose wall structure is similar to the arteries of the muscular type. V. prostatica is a small-size valved vein. The canine prostate has capsular, parenchymal, and urethral vascular zones. The surface vessels of the capsule are predominantly veins and the diameter of arterial vessels is larger than that of the veins. The trabecular vessels are of two types: direct and branched. The prostate parenchyma is supplied by branches of the trabecular vessels. The periacinary capillaries are fenestrated and form a net in a circular pattern. The processes of the myoepithelial cells embrace both the acins and the periacinar capillaries. In the prostate ductal system. there are spermatozoa. The prostatic part of the urethra is supplied by an independent branch of a. prostatica. The prostatic urethral part is drained by v. prostatica, the vein of the urethral bulb and the ventral prostate veins. M. urethralis begins as early as the urethral prostatic part. The greater part of the white muscle fibers in m. urethralis suggest an enhanced anaerobic metabolism. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2004        PMID: 14988915     DOI: 10.1002/jemt.20028

Source DB:  PubMed          Journal:  Microsc Res Tech        ISSN: 1059-910X            Impact factor:   2.769


  6 in total

1.  Prostatic arterial embolization for the treatment of lower urinary tract symptoms due to large (>80 mL) benign prostatic hyperplasia: results of midterm follow-up from Chinese population.

Authors:  Mao Qiang Wang; Li Ping Guo; Guo Dong Zhang; Kai Yuan; Kai Li; Feng Duan; Jie Yu Yan; Yan Wang; Hai Yan Kang; Zhi Jun Wang
Journal:  BMC Urol       Date:  2015-04-16       Impact factor: 2.264

2.  Prostatic hyperplasia: Vascularization, hemodynamic and hormonal analysis of dogs treated with finasteride or orchiectomy.

Authors:  Daniel S R Angrimani; Maria Claudia P Francischini; Maíra M Brito; Camila I Vannucchi
Journal:  PLoS One       Date:  2020-06-25       Impact factor: 3.240

3.  Reproductive and endocrinological effects of Benign Prostatic Hyperplasia and finasteride therapy in dogs.

Authors:  Daniel S R Angrimani; Maíra M Brito; Bruno R Rui; Marcílio Nichi; Camila I Vannucchi
Journal:  Sci Rep       Date:  2020-09-09       Impact factor: 4.379

4.  Effect of pulsed electromagnetic field therapy on prostate volume and vascularity in the treatment of benign prostatic hyperplasia: a pilot study in a canine model.

Authors:  Raffaella Leoci; Giulio Aiudi; Fabio Silvestre; Elaine Lissner; Giovanni Michele Lacalandra
Journal:  Prostate       Date:  2014-06-09       Impact factor: 4.104

5.  Prostatic Arterial Embolization with Small Sized Particles for the Treatment of Lower Urinary Tract Symptoms Due to Large Benign Prostatic Hyperplasia: Preliminary Results.

Authors:  Qiang Li; Feng Duan; Mao-Qiang Wang; Guo-Dong Zhang; Kai Yuan
Journal:  Chin Med J (Engl)       Date:  2015-08-05       Impact factor: 2.628

Review 6.  Canine prostate models in preclinical studies of minimally invasive interventions: part I, canine prostate anatomy and prostate cancer models.

Authors:  Fei Sun; Claudia Báez-Díaz; Francisco Miguel Sánchez-Margallo
Journal:  Transl Androl Urol       Date:  2017-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.